Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: Ruxolitinib
Sponsors: University of California, San Francisco; Incyte Pharmaceuticals
Not yet recruiting - verified May 2017
http://ift.tt/2qlaDm3
http://ift.tt/2qlO7ct
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 8 April 2017 Source: European Journal of Vascular and Endovascular Surgery Author(s): J.P. Archie ...
-
Epidemiology and predictive factors of fungal malignant otitis externa Rim Bechraoui, Mohamed Dhaha, Houda Chahed, Amal Ksentini, Rim Zainin...
-
Testicular tumours are the most common tumours in young men. Germ cell tumours (GCTs) account for 95% of all testicular cancers, and the non...
-
Abstract The potential for cardiac implantable electronic device leads to interfere with tricuspid valve (TV) function has gained increasin...
-
The original version of this article unfortunately contained a mistake in the author name. The co-author name should be Hiroyuki Matsuura in...
-
Publication date: Available online 28 February 2017 Source: Neuroscience Research Author(s): Soshi Tanabe, Ken-ichi Inoue, Hitomi Tsuge, ...
-
Abstract Background HIV progression is characterized by immune activation and microbial translocation from the gut. Short-chain fatty ac...
-
Abstract Background Oral semaglutide is a novel tablet containing the human glucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-for...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου